Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing the levels of incretin hormones, which stimulate insulin release and decrease glucagon production. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing The recommended dose is 5 mg orally once daily. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients. ## Dose Adjustments No dose adjustment is required for patients with renal or hepatic impairment. ## Contraindications * Hypersensitivity to linagliptin or any excipient in the formulation. * History of serious hypersensitivity reactions to linagliptin. ## Adverse Effects The most common adverse effects include hypoglycemia (especially when used with sulfonylureas or insulin), nasopharyngitis, cough, and diarrhea. Rare but serious adverse effects include angioedema, urticaria, rash, pancreatitis, and severe joint pain. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., rifampin):** May decrease linagliptin exposure and efficacy. If coadministration is necessary, careful glucose monitoring is advised. * **Sulfonylureas and Insulin:** Increased risk of hypoglycemia; dose reduction of sulfonylurea or insulin may be considered. ## Monitoring * Monitor blood glucose levels for glycemic control. * Assess for signs and symptoms of hypoglycemia, especially if used concurrently with insulin or sulfonylureas. * Monitor for signs of hypersensitivity reactions (e.g., angioedema, rash). * Monitor for signs and symptoms of pancreatitis (e.g., persistent severe abdominal pain). ## Clinical Pearls * Linagliptin has a low risk of hypoglycemia when used as monotherapy due to its insulinotropic effect being glucose-dependent. * It is primarily eliminated unchanged in bile and feces, hence no dose adjustment is needed in renal impairment. * Consider DPP-4 inhibitors as an option when prolonged glycemic control is desired with a low risk of weight gain and hypoglycemia. *** **Disclaimer:** This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for accurate and comprehensive guidance.